By Michael Susin

AstraZeneca has agreed to settle product liability litigations related to Nexium and Prilosec in the U.S. by making a payment of $425 million, it said.

The Anglo-Swedish pharma giant said Tuesday that it has resolved the litigations under confidential terms.

The settled claims were pending in the Multidistrict Litigation District Court of New Jersey, as well as in the Delaware Superior Court and the New Jersey Superior Court.

The company said a single case remains pending in the U.S. District Court for the Middle District of Louisiana. Trial is scheduled for April 15, 2024.

Nexium and Prilosec are used to treat acid-related symptoms.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

October 03, 2023 02:32 ET (06:32 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Nov 2023 a Dic 2023 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Dic 2022 a Dic 2023 Clicca qui per i Grafici di Astrazeneca